Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin + omega-3 and colchicine for recovery after COPD exacerbation
ISRCTN41823570Phase 3Recruiting
- Sponsor
- Cambridge Clinical Trials Unit
- Start
- Jul 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of aspirin, omega-3 fatty acid and colchicine in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Cambridge Clinical Trials Unit. Primary endpoint: Treatment failure by 12 weeks. Started Jul 2026; status: recruiting.
02
Drugs
aspirinomega-3 fatty acidcolchicine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ISRCTN41823570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN41823570.